
    safety reason
  
['plaque psoriasis']
['agn-242428', 'placebo']

        Inclusion Criteria:

          -  Participants who have a confirmed diagnosis of plaque psoriasis, diagnosed at least 6
             months before study with a Physician's Global Assessment (PGA) score ≥ 3 at screening
             and baseline

          -  Severity of disease must be at least moderate, defined as Psoriasis Area and Severity
             Index (PASI) ≥ 12 and % body surface area (BSA) ≥ 10

          -  Participant is a candidate for phototherapy or systemic therapy for psoriasis

          -  Body weight of at least 55 kilograms (kg) (121 (pound) lbs)

        Exclusion Criteria:

          -  Non-plaque forms of psoriasis (erythrodermic, guttate, pustular) or drug-induced
             psoriasis

          -  Psoriasis which has not been stable for the 4 weeks prior to screening and which is
             unstable at Study Day 1

          -  History of Gilbert's, Rotor, or Dubin-Johnson syndromes or any other disorder of
             bilirubin metabolism

          -  History of active mycobacterium tuberculosis (TB) infection or untreated or
             inadequately treated latent TB

          -  Positive QuantiFERON test for TB infection at screening

          -  Had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months prior to
             baseline

          -  Positive drug and/or alcohol test at screening (with the exception of marijuana).
             Retesting in the case of a positive alcohol test is allowed at the discretion of the
             sponsor

          -  Current treatment or history of treatment with any anti-Tumor Necrosis Factor alpha
             (TNFα) biologic therapy within 3 months or 5 half-lives of study, and/or all other
             biologics within 6 months of study (Day 1)

          -  Efficacy failure on 2 or more biologic agents for the treatment of psoriasis when the
             failures occurred within 1 year of the initiation of the therapy of the first biologic
             agent

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin
             (TBL) exceeding 1.5 times the upper limit of normal (ULN) at screening.
      